The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...